Parkman Healthcare Partners LLC Has $3.38 Million Stock Holdings in Silence Therapeutics plc (NASDAQ:SLN)

Parkman Healthcare Partners LLC cut its stake in shares of Silence Therapeutics plc (NASDAQ:SLN) by 1.4% in the 4th quarter, HoldingsChannel.com reports. The firm owned 491,080 shares of the company’s stock after selling 6,790 shares during the quarter. Parkman Healthcare Partners LLC’s holdings in Silence Therapeutics were worth $3,379,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of SLN. JPMorgan Chase & Co. acquired a new position in Silence Therapeutics during the fourth quarter valued at approximately $26,000. GAMMA Investing LLC raised its stake in Silence Therapeutics by 609.2% in the fourth quarter. GAMMA Investing LLC now owns 6,092 shares of the company’s stock valued at $42,000 after buying an additional 5,233 shares during the period. Barclays PLC raised its stake in Silence Therapeutics by 83.8% in the fourth quarter. Barclays PLC now owns 6,126 shares of the company’s stock valued at $42,000 after buying an additional 2,793 shares during the period. China Universal Asset Management Co. Ltd. bought a new stake in Silence Therapeutics in the fourth quarter valued at approximately $69,000. Finally, Virtus ETF Advisers LLC raised its stake in Silence Therapeutics by 130.5% in the fourth quarter. Virtus ETF Advisers LLC now owns 10,772 shares of the company’s stock valued at $74,000 after buying an additional 6,098 shares during the period. 98.73% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have issued reports on SLN. Chardan Capital dropped their price objective on Silence Therapeutics from $55.00 to $35.00 and set a “buy” rating on the stock in a research note on Friday, May 9th. BMO Capital Markets reduced their target price on Silence Therapeutics from $67.00 to $25.00 and set an “outperform” rating on the stock in a report on Tuesday, March 4th. The Goldman Sachs Group reduced their target price on Silence Therapeutics from $4.00 to $3.00 and set a “sell” rating on the stock in a report on Friday, May 9th. HC Wainwright reaffirmed a “buy” rating and issued a $75.00 target price on shares of Silence Therapeutics in a report on Friday, March 7th. Finally, Morgan Stanley reduced their target price on Silence Therapeutics from $45.00 to $25.00 and set an “overweight” rating on the stock in a report on Friday, May 9th. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Silence Therapeutics has an average rating of “Moderate Buy” and an average target price of $33.83.

Silence Therapeutics Price Performance

Shares of SLN opened at $4.11 on Wednesday. The firm has a market cap of $123.01 million, a PE ratio of -2.62 and a beta of 1.20. The stock’s fifty day moving average price is $3.36 and its two-hundred day moving average price is $6.30. Silence Therapeutics plc has a 1 year low of $1.97 and a 1 year high of $24.38.

Silence Therapeutics (NASDAQ:SLN) last announced its earnings results on Thursday, May 8th. The company reported ($0.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.42). The business had revenue of $0.14 million during the quarter, compared to the consensus estimate of $3.58 million. Silence Therapeutics had a negative return on equity of 62.81% and a negative net margin of 342.00%. Sell-side analysts anticipate that Silence Therapeutics plc will post -1.77 earnings per share for the current fiscal year.

Silence Therapeutics Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.